Synaptogenix Inc (SNPX)

[InTheTrenches]

This abstract analyzes post-marketing data from GH use in PEDIATRIC population.

There is a reason that THE FDA requires companies to test many drugs in pediatric trials before they can be used in that population—the reaction of some drugs in a developing, immature body can be very different and have different side effects than in an adult patient. It’s apples and oranges to extrapolate pediatric side-effects to adult side-effects.

The average age of the targeted population for bryostatin will probably be about 65-70!

There is the possibility that the FDA will require a post-marketing study on theoretical risks (this is common for many drugs), but I can’t foresee this as a reason to deny approval of a drug that may reverse a deadly disease—Alzheimer’s.